این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Acta Medica Iranica، جلد ۵۷، شماره ۱۱، صفحات ۶۲۷-۶۳۴
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Effects of Celecoxib on electroconvulsive therapy-induced cognitive impairment in patients with major depressive disorder: a pilot, double-blind, placebo-controlled trial
چکیده انگلیسی مقاله Objective. Cognitive impairment, an important side effect of electroconvulsive therapy (ECT), may be related to the release of prostaglandins in the brain. Cyclooxygenase-2 (COX-2), constitutively expressed in the CNS, has a functional role in the glutamate-mediated learning and memory. The goal of this pilot, double-blind, placebo-controlled trial was to evaluate the effects of the selective COX-2 inhibitor Celecoxib on the adverse cognitive effects of ECT. Methods. Twenty patients diagnosed with major depressive disorder for which ECT was indicated as a treatment for their current episode randomly received either Celecoxib (200 mg orally twice a day, total dose of 400 mg/day) or placebo. All patients underwent the same protocol for anesthesia and ECT procedures. The patients received Celecoxib or the placebo for the whole period of ECT treatment, starting the day before ECT and continuing until the sixth (last) session of ECT. The Wechsler Mental Scale-III (WMS-III), the Mini Mental Scale Examination (MMSE) and Stroop Color test were used to assess cognition before the first session and after the first, third and sixth sessions of ECT. Hamilton rating scale for depression was also used for assessment of depression before and after the trial. Results. Our data showed that Celecoxib group did not have significant improvement in cognition based on WMS-III or MMSE scores. There was an improvement in Stroop Color test but not statistically significant.  Conclusion. Our results demonstrated that although Celecoxib was well tolerated in patients undergoing ECT, it did not improve related cognitive impairment. Clinical trial registration number: IRCT201201247202N2.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Nafiseh Banaha
School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Department of Psychiatry, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337-95914, Iran; Massachusetts College of Pharmacy and Health Sciences, 19 Foster Street, Worcester, MA 01608, USA.


| Padideh Ghaeli
Department of Psychiatry, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337-95914, Iran; Faculty of Pharmacy, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337-95914, Iran.


| Abolghasem Yousefi
Department of Psychiatry, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337-95914, Iran; Department of Anesthesiology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran.


| Valentin Artounian
Department of Psychiatry, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, South Kargar Street, Tehran 13337-95914, Iran.


| Mohammad H. Afzali
Department of Psychiatry, University of Montreal, Montreal, Quebec H3C 3J7, Canada.


| Mehdi Ghasemi
Department of Neurology, University of Massachusetts Medical School
نشانی اینترنتی http://acta.tums.ac.ir/index.php/acta/article/view/7946
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/56/article-56-2410538.pdf
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات